

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**ENTERING AN EXCLUSIVE DISTRIBUTION AND
PROMOTION AGREEMENT WITH PHARMENTUM BIOPHARMA
TO COMMERCIALIZE EPINASTINE HYDROCHLORIDE EYE DROPS
IN CHINA (EXCLUDING HONG KONG, MACAU AND TAIWAN)**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the Company has recently entered into an Exclusive Distribution and Promotion Agreement for Epinastine Hydrochloride Eye Drops covering all sales channels in China (excluding Hong Kong, Macau and Taiwan) with Pharmentum Biopharma (Beijing) Co., Ltd. (“**Pharmentum Biopharma**”). Under the agreement, the Company and Pharmentum Biopharma will cooperate for an initial term of five years. If Pharmentum Biopharma achieves at least 80% of the cumulative procurement target during the initial five-year period and there are no other material breaches of the agreement, the cooperation term shall be automatically renewed once, extending the total contract term to ten years.

ABOUT EPINASTINE HYDROCHLORIDE EYE DROPS

Epinastine Hydrochloride Eye Drops is a self-developed generic drug of the Company (the “**Product**”). Epinastine Hydrochloride Eye Drops were approved for marketing by the National Medical Products Administration (“**NMPA**”) on November 19, 2025, for the treatment of symptoms associated with seasonal allergic conjunctivitis. Validated through a conjunctival allergen challenge (CAC) model, the Product demonstrates a rapid onset of action within 3 minutes of administration, with efficacy lasting for at least 8 hours. The Product has also shown a favorable overall safety and tolerability profile. The Product is a generic version of Elestat®.

Epinastine Hydrochloride Eye Drops exhibit a dual mechanism of action, combining antihistamine activity and mast cell stabilization, making it a first-line foundational therapy for allergic conjunctivitis. On the one hand, it acts as a potent and selective H1 receptor antagonist, competitively blocking histamine H1 receptors and effectively relieving early-phase symptoms such as itching and conjunctival redness caused by histamine release. On the other hand, it stabilizes mast cells and inhibits mast cell degranulation, thereby reducing the release of histamine, leukotrienes, and other inflammatory mediators, and intervening in the early stage of Type I hypersensitivity reactions. In addition, the drug exhibits a certain degree of affinity for H2 receptors, α -adrenergic receptors, and 5-HT receptors, which may contribute to the modulation of inflammatory responses and provide additional therapeutic benefits.

ABOUT ALLERGIC CONJUNCTIVITIS (“AC”)

Allergic conjunctivitis (“AC”) is an ocular disorder characterized by hypersensitivity reactions of the conjunctiva to allergen exposure – such as environmental pollutants, pet dander, pollen, and house dust mites. Typical clinical manifestations include ocular pruritus, ocular foreign body sensation, and increased conjunctival secretions. Patients suffer from unbearable eye itching during episodes. As complete avoidance from allergens is unachievable, patients frequently experience recurrent episodes. This condition commonly restricts outdoor activities and severely impairs patients’ daily life and work.

ABOUT PHARMENTUM BIOPHARMA (BEIJING) CO., LTD.

Pharmentum Biopharm takes as its mission to make innovative consumer medicines accessible to people around the globe and endeavors to grow into the most trusted consumer health enterprise. Pharmentum Biopharma’s core team members hail from leading internet healthcare platforms, multinational pharmaceutical enterprises and top consulting firms, with professional strengths covering China’s prescription drug e-commerce and digital marketing sectors. Pharmentum Biopharma’s legal representative is Jin Enlin, who served as CEO at Jd Health International Inc. from 2021 to 2025 and has accumulated in-depth experience in full-channel pharmaceutical supply chains and the closed-loop medical and healthcare service ecosystem.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee the future sales revenue of Epinastine Hydrochloride Eye Drops. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, August 12, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as Executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.